We are live on ! Find out more
TERN

Terns Pharmaceuticals
TERN

Delisted

TERN was delisted on the 4th of May, 2026.

Back to rankings

103 hedge funds and large institutions have $505M invested in Terns Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 16

32% more funds holding

Funds holding: 78 → 103 (+25)

32% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 22

7.93% more ownership

Funds ownership: 93.9% → 101.83% (+7.9%)

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

20% less capital invested

Capital invested by funds: $630M → $505M (-$125M)

69% less call options, than puts

Call options by funds: $3.35M | Put options by funds: $10.7M

Holders
103
Holders Change
+25
Holders Change %
+32.05%
% of All Funds
1.62%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.09%
New
41
Increased
29
Reduced
22
Closed
16
Calls
$3.35M
Puts
$10.7M
Net Calls
-$7.38M
Net Calls Change
-$7.38M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$28.4M
2
SCM
Suvretta Capital Management
New York
+$24.6M
3
Millennium Management
Millennium Management
New York
+$14M
4
DTC
Deep Track Capital
Connecticut
+$12.8M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$10.9M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$15.7M
2
DCM
Driehaus Capital Management
Illinois
-$9.88M
3
VA
VR Adviser
New York
-$7.54M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.45M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
76
T. Rowe Price Associates
Maryland
$149K +$198K +16,986 New
Manulife (Manufacturers Life Insurance)
77
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$147K +$196K +16,836 New
Squarepoint
78
Squarepoint
New York
$139K +$34.3K +2,946 +23%
Citigroup
79
Citigroup
New York
$127K -$360K -30,884 -68%
PI
80
PEAK6 Investments
Illinois
$123K +$164K +14,097 New
State Board of Administration of Florida Retirement System
81
State Board of Administration of Florida Retirement System
Florida
$106K +$142K +12,170 New
DTL
82
Dynamic Technology Lab
Singapore
$106K +$141K +12,101 New
CF
83
Crosspoint Financial
California
$105K – – –
Zurich Cantonal Bank
84
Zurich Cantonal Bank
Switzerland
$100K +$105K +8,973 +362%
AGM
85
Alpine Global Management
New York
$93.2K +$124K +10,655 New
VEA
86
Virtus ETF Advisers
New York
$80.8K +$108K +9,239 New
TRCT
87
Tower Research Capital (TRC)
New York
$70.1K +$50.8K +4,361 +119%
AB
88
Amalgamated Bank
New York
$50K +$66.5K +5,705 New
AIP
89
Ameritas Investment Partners
Nebraska
$31K +$41.2K +3,539 New
TAM
90
Tucker Asset Management
Colorado
$24.7K +$32.9K +2,824 New
ACM
91
Aquatic Capital Management
Illinois
$21K +$26.8K +2,300 +2,300%
MLICM
92
Metropolitan Life Insurance Company (MetLife)
New York
$21K +$27.9K +2,395 New
Citadel Advisors
93
Citadel Advisors
Florida
$12.7K -$4.55M -390,609 -100%
CUAMC
94
China Universal Asset Management Company
China
$6.5K +$839 +72 +11%
S
95
SignatureFD
Georgia
$2.25K +$1.79K +154 +150%
CAL
96
Capital Advisors Ltd
Ohio
$2K – – –
IPW
97
Impact Partnership Wealth
Georgia
$1.99K +$2.65K +227 New
Federated Hermes
98
Federated Hermes
Pennsylvania
$1.47K +$1.96K +168 New
PA
99
Parallel Advisors
California
$1.41K – – –
Daiwa Securities Group
100
Daiwa Securities Group
Japan
$1K – – –
1 2 3
4
5

TERN Hedge Fund Activity: Q2 2023 in Review

103 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q2 2023, worth a combined $505M — down 20% from $630M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new TERN positions and 16 closed out — a net gain of 25 holders — while 29 added to existing stakes and 22 trimmed.

The largest buyer was BlackRock, adding an estimated $28.4M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $15.7M sold.

  • 103 institutional investors held Terns Pharmaceuticals (TERN) as of Q2 2023, up from 78 in Q1 2023.
  • Funds reported $505M of Terns Pharmaceuticals stock for Q2 2023, down 20% quarter-over-quarter.
  • 41 funds opened new Terns Pharmaceuticals positions in Q2 2023 and 16 closed out, a net change of +25 holders.
  • The largest Terns Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $28.4M added.
  • The largest Terns Pharmaceuticals seller in Q2 2023 was Perceptive Advisors, an estimated $15.7M sold.

Based on aggregated 13F filings for Q2 2023.